DINNER SHORT COURSE: THURSDAY, APRIL 28
Critical Considerations for the Design and Development of Antibody-Drug Conjugates
Instructors:
Mohammad Tabrizi, Ph.D., Senior Fellow and Head, PK/PD, Merck
Isabel Figueroa, Ph.D., Scientist, PTPK Department, Genentech
Shawn
Owen, Ph.D., Assistant Professor, Pharmaceutical Chemistry, University of Utah
Objectives:
Antibody Drug Conjugates are increasingly employed as novel targeted therapies. They consist of an antibody, a linker and a payload. ADC can combine the exquisite selectivity of antibodies with the therapeutic activity of small molecule drugs to achieve
the desired therapeutic objectives. Achieving the desired therapeutic outcome, when using an ADC candidate, will depend on attributes related to the target, antibody, linker, and the payload. In this course, we have attempted to evaluate some of the
key topics important for design and development of this class of therapeutics:
Course Outline:
Introduction
Mohammad Tabrizi, Ph.D., Senior Fellow and Head, PK/PD, Merck
Considerations for Design and Selection of ADCs
Isabel Figueroa, Ph.D., Scientist, PTPK Department, Genentech
Design and Selection of Linker, Payload and Conjugation Chemistry
Shawn Owen, Ph.D., Assistant Professor, Pharmaceutical Chemistry, University of Utah
Translational Considerations: Path to the Clinic
Mohammad Tabrizi, Ph.D., Senior Fellow and Head, PK/PD, Merck